Recordati S.p.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Koremans
- Full Time Employees
- 4,693
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Via Matteo Civitali,1 Milan MI Italy 20148
- IPO Date
- Jan 1, 1984
- Website
- recordati.com
- Similar Companies
- Business
- Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI) is an Italy-based international pharmaceutical group dedicated to the research, development, manufacturing, and marketing of prescription and non-prescription pharmaceuticals, pharmaceutical chemicals, and therapeutic products for specialty care, primary care, consumer healthcare, and rare diseases; its core offerings encompass active pharmaceutical ingredients such as Aciclovir, Verapamil Hydrochloride, Sertraline Hydrochloride, Dobutamine Hydrochloride, Ketorolac Tromethamine, and intermediates like Tetrahydropapaverine, alongside finished medicines addressing common diseases and rare conditions including Cushing’s syndrome via Isturisa (osilodrostat), which recently received FDA expanded indication for endogenous hypercortisolemia. Founded in 1926 in Correggio, Italy, and headquartered in Milan with approximately 4,450-4,580 employees across 10 plants including sites in Italy, Ireland, and Tunisia, the company operates in around 150 countries spanning Europe, Russia and CIS countries, Turkey, North Africa, the United States, Canada, Mexico, South America, Japan, and Australia through subsidiaries such as Recordati Rare Diseases, Casen Recordati, Jaba Recordati, and Recordati Ilaç. Recent developments include the 2024 agreement to acquire global rights to Enjaymo (sutimlimab) from Sanofi to bolster its rare diseases portfolio, preliminary 2024 results showing revenue growth of 12.4%, EBITDA up 12.5%, and adjusted net income up 8.4% with raised peak sales targets for key rare disease products, alongside earlier expansions like the acquisition of EUSA Pharma in the UK for rare diseases and endocrinology and new subsidiaries in Japan and Australia.
Company News
RECORDATI ANNOUNCES THE WINNER OF THE 12TH EDITION OF THE ARRIGO RECORDATI PRIZE FOR SCIENTIFIC RESEARCH
RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%
RECORDATI: PROSEGUE IL SOLIDO SLANCIO DI CRESCITA DEL GRUPPO NEL PRIMO SEMESTRE DEL 2026 RICAVI NETTI +6,6%, EBITDA +8,8%, UTILE NETTO RETTIFICATO +6,7%
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%
RECORDATI: IL FORTE SLANCIO DEL GRUPPO PROSEGUE NEL PRIMO TRIMESTRE DEL 2026 RICAVI NETTI +4,9%, EBITDA(1) +5,0%, UTILE NETTO RETTIFICATO(2) +7,2%
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION